by Lorenzo Monasta | Mar 29, 2024 | Infectious diseases and AMR, Italian GBD Initiative
By 2050, it is estimated that antimicrobial resistance (AMR) will cause 10 million annual deaths worldwide, costing up to $100 trillion. Antibiotic resistance (ABR) is the most significant health threat and, in 2019, caused 1.27 million deaths globally. One in 5...
by Lorenzo Monasta | Mar 29, 2024 | Uncategorized
As little is known about the burden of type 1 (T1DM) and type 2 diabetes (T2DM) in adolescents in Western Europe (WE), we aimed to explore their epidemiology among 10-24 year-olds. Estimates were retrieved from the Global Burden of Diseases Study (GBD) 2019. We...
by Lorenzo Monasta | Mar 29, 2024 | Italian GBD Initiative, Non-communicable diseases
Patients with type 2 diabetes mellitus (T2DM) are rapidly increasing in Italy due to aging, preventable risk factors, and a worsening socioeconomic environment. T2DM and its consequences take a heavy toll on health care systems and the economy, given the costly...
by Lorenzo Monasta | Nov 6, 2023 | Infectious diseases and AMR, Italian GBD Initiative
In 2016, the World Health Assembly adopted the resolution to eliminate viral hepatitis by 2030. A GBD study led by the University of Milan-Bicocca, published in the journal The Lancet Public Health, aimed to provide an overview of the impact of hepatitis B virus (HBV)...
by Lorenzo Monasta | Aug 16, 2023 | Cardiovascular disease, Environmental exposures, Italian GBD Initiative, Tumors
Air pollution is one of the risk factors assessed by the Global Burden of Disease Study and is of great importance in population health. It actually ranks fourth in terms of impact on a global scale. Since it is known that air quality in Italy has peculiar...